Photo of Professor Kholoud Porter

Professor Kholoud Porter

Professor in Epidemiology: University College London

P.O. Box 198
Mtubatuba 3935
South Africa

E: This email address is being protected from spambots. You need JavaScript enabled to view it.
T: +27 (0)35 5507509

  • EuroCoord (European network of HIV/AIDS cohort studies to coordinate at European and International level clinical research on HIV/AIDS), funded by European Union FP7 (260694) - Principal Investigator
  • Health Protection Research Unit in Blood-borne Viruses and Sexually Transmitted Infections, funded by NIHR (HPRU-2012-10023) - Collaborator
  • BEEHIVE (Bridging the Evolution And Epidemiology of HIV in Europe) funded by European Research Council - Collaborator
  • NesCent (National Evolutionary Synthesis Center) grant on HIV evolution - Collaborator
  • HGC (HIV Genomics Consortium) funded by Wellcome Trust Sanger Centre - Collaborator
  • HEATHER (HIV Reservoir targeting with Early Antiretroviral Therapy)-  Collaborator

2015

  1. Hamlyn E, Stöhr W, Cooper DA, Fisher M, Tambussi G, Schechter M, Miro JM, Vanobberghen F, Babiker A, Weber J, McClure M, Porter K and Fidler S On Behalf Of The SPARTAC Investigators. The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on Interleukin-6 and D-dimer levels. AIDS 2015 (In Press).

2014

  1. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS on behalf of the UK HIV Genomics Consortium. A Systematic Review of Definitions of Extreme Phenotypes of HIV Control and Progression. AIDS 2014;28:149-62.
  2. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix M, Amornkul P, Babiker A, Sandhu MS, Porter K for CASCADE Collaboration in EuroCoord. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. PLoS One 2014;9:e86719
  3. Hamlyn E, Fidler S, Stöhr W, Cooper DA, Tambussi G, Schechter M, Miro JM, McClure M, Weber J, Babiker A, Porter K for SPARTAC Trial Investigators. IL-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression. AIDS 2014;28:869-74.
  4. Frater J, Ewings F, Hurst J, Brown H, Robinson N, Fidler S, Babiker A, Weber J, Porter K, Phillips RE on behalf of the SPARTAC Trial Investigators. HIV-1 Specific CD4 Responses in Primary HIV-1 Infection predict disease progression: the SPARTAC Trial. AIDS 2014;28:699-708.
  5. Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla PG, Guest J, Samji H, Castagna A, d'Arminio Monforte A, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher HC, De Wit S, Burkholder GA, Teira R, Justice AC, Sterling TR, M Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle SM, Sterne J, Obel N; Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clin Infect Dis 2014;58:1312-21.
  6. Olson AD, Guiguet M, Zangerle R, Gill J, Perez-Hoyos S, Lodi S, Ghosn J, Dorrucci M, Johnson A, Sannes M, Moreno S, Porter K for CASCADE Collaboration in EuroCoord. Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype.  JAIDS 2014;67:15-21.
  7. May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, Hay P, Johnson M, Palfreeman A, Gilson R, Chadwick D, Martin F, Hill T, Walsh J, Post F, Fisher M, Ainsworth J, Jose S, Leen C, Nelson M, Anderson J, Sabin C; for the UK Collaborative HIV Cohort (UK CHIC) Study. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy: UK cohort study. AIDS 2014;28:1193-202.
  8. van der Helm JJ, Geskus R, Lodi S, Meyer L, Schuitemaker H, Gunsenheimer-Bartmeyer B, d'Arminio Monforte A, Olson A, Touloumi G, Sabin C, Porter K, Prins M on behalf of CASCADE Collaboration in EuroCoord. Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. Lancet HIV 2014;1;e41–e48.
  9. Pantazis N, Porter K, Costagliola D, De Luca A, Ghosn J, Guiguet M, Johnson A, Kelleher AD, Morrison C, Thiebaut R, Wittkop L and Touloumi G on behalf of CASCADE Collaboration in EuroCoord. Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study. Lancet HIV 2014;1:e119–e126.
  10. Case KK, Hallett TB, Gregson S, Porter K, Ghys PD. Development and future directions for the Joint United Nations Programme on HIV/AIDS estimates. AIDS 2014;28 Suppl 4:S411-4

2013

  1. Rosinska M, Marzec-Boguslawska A, Janiec J, Smoleń-Dzirba J, Wąsik T, Gniewosz J, Zalewska M, Murphy G, McKinney E, Porter K. High percentage of recent HIV infection among HIV-positive individuals newly-diagnosed at voluntary counselling and testing sites in Poland. AIDS Res Hum Retroviruses 2013;29:805-13.
  2. SPARTAC Trial Investigators, Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, Rees H, Fisher M, Schechter M, Kaleebu P, Tambussi G, Kinloch S, Miro JM, Kelleher A, McClure M, Kaye S, Gabriel M, Phillips R, Weber J, Babiker A. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013;368:207-17.
  3. van der Helm J, Geskus R, Sabin C, Meyer L, Del Amo J, Chêne G, Dorrucci M, Muga R, Porter K, Prins M; CASCADE collaboration in EuroCoord.  Effect Of HCV Infection On Cause-Specific Mortality Following HIV Seroconversion Before And After 1997. .
  4. Touloumi G, Pantazis N, Pillay D, Paraskevis D, Chaix ML, Bucher HC, Kücherer C, Zangerle R, Kran AM, Porter K; on behalf of the CASCADE collaboration in EuroCoord. Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts. Clin Infect Dis 2013 2013;56:888-97.
  5. Lodi S, Del Amo J, d'Arminio Monforte A, Abgrall S, Sabin C, Morrison C, Furrer H, Muga R, Porter K, Girardi E; on behalf of the CASCADE collaboration in EuroCoord. Risk of tuberculosis following HIV seroconversion in high-income countries. Thorax 2013;68:207-13.
  6. Madec Y, Boufassa F, Porter K, Prins M, Sabin C, d’Arminio Monforte A, Amornkul P, Bartmeyer B, Sannes M, Venet A, Lambotte O and Meyer L on behalf of the CASCADE Collaboration in Eurocoord. Natural History of HIV control since seroconversion: experience from the CASCADE collaboration. AIDS 2013;27:2451-60.
  7. Simmons R, Semeneko I, Tolpina M, Tereschenko R, Kotlik L, Zasyptka L, Murphy G, McKinney E, Copas A, Malyuta R, Porter K. High percentage of recent HIV infection leading to onward transmission in Odessa, Ukraine associated with young adults. AIDS Behav 2013;18:411-8.
  8. Touloumi G, Pantazis N, Chaix ML, Bucher H C, Zangerle R, Bakken Kran AM, Thiebaut R, Masquelier B, Kucherer C, d’Arminio Monforte A, Meyer L and Porter K for CASCADE Collaboration in EuroCoord. Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE Collaboration. PLoS ONE 2013;8:e71174.
  9. Weber J, Porter K, Babiker A. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013;368:2036-7
  10. Lodi S, Phillips A, Fidler S, Hawkins D, Gilson R, McLean K, Fisher M, Post F, Johnson AM, Walker-Nthenda L, Dunn D, Porter K on behalf of the UK Register of HIV Seroconverters. Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of virological failure. PLoS ONE 2013;8: e75608.
  11. Porter K, Lodi S, Meyer L. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion--reply. JAMA Intern Med 2013;173:476-7.
  12. Stöhr W, Fidler S, McClure M, Weber J, Cooper D, Ramjee G, Kaleebu P, Tambussi G, Schechter M, Babiker A, Phillips R, Porter K, Frater J on behalf of the SPARTAC Trial Investigators. Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy. PLOS ONE 2013;8:e78287.
  13. Lodi S, Fisher M, Phillips A, De Luca A, Ghosn J, Malyuta R, Zangerle R, Moreno S, Vanhems P, Boufassa F, Guiguet M, Porter K for CASCADE Collaboration in EuroCoord. Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection. PLoS One 2013;8:e78642.
  14. Huang X, Lodi S, Fox Z, Li W, Phillips A, Porter K, Lutsar I, Kelleher A, Li N, Xu X, Wu H, Johnson AM; on behalf of the Beijing PRIMO cohort study and the CASCADE Collaboration in EuroCoord. Rate of CD4 decline and HIV-RNA change following HIV Seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts. J Acquir Immune Defic Syndr 2013;62:441-6.

2012

  1. Jarrin I, Pantazis N, Gill J, Geskus R, Perez-Hoyos S, Meyer L, Prins M, Touloumi G, Johnson A, Hamouda O, García de Olalla P, Porter K, del Amo J. Differences in uptake of combination antiretroviral therapy (cART) and HIV disease progression according to geographical origin. Clin Infect Dis. 2012; 54: 111-8.
  2. Hamlyn E, Hickling S, Porter K, Frater J, Phillips R, Robinson M, Mackie NE, Kaye S, McClure M, and Fidler S on behalf of the SPARTAC Investigators. Increased levels of CD4 T-cell activation in individuals with CXCR4 using viruses in Primary HIV-1 infection.  AIDS 2012;26:887-90.
  3. Zugna D, Geskus RB, De Stavola B, Rosinska M, Bartmeyer B, Boufassa F, Chaix M, Babiker A and Porter K for the CASCADE Collaboration in EuroCoord. Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection. Antiviral Therapy 2012;17:1039-48.
  4. Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G on behalf of CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group. Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PLoS One. 2012; 7: e32369.
  5. de Wolf F, Sabin C, Kirk O, Thorne C, Chene G, Porter K for EuroCoord. Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience. Clin Invest 2012;2:255-264.
  6. Lodi S, Meyer L, Kelleher A, Rosińska M, Ghosn J, Sannes M, Porter K for the CASCADE Collaboration in EuroCoord. Immuno-virological control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med 2012;172:1252-5.
  7. Smoleń-Dzirba J, Rosińska M, Kruszyński P, Bratosiewicz- Wąsik J, Janiec J, Beniowski M, Bociąga-Jasik M, Jabłonowska E, Szetela B, Porter K, Wąsik T, and the CASCADE collaboration in EuroCoord. Molecular epidemiology of recent HIV-1 infections 1 in southern Poland. J Med Virol 2012;84:1857-68.
  8. Hoskins S, Jahn A, Somi G, Semenenko I, Kirungi W, Kaleebu P, Phiri S, Malyuta R, Fakoya A, Weller I, Porter K. Evaluating the systems used to monitor HIV populations accessing therapy and care in low-income and lower-middle-income countries.  AIDS 2012;26 Suppl 2:S137-45.
  9. Hamlyn E, Ewings FM, Porter K, Cooper DA, Tambussi G, Schechter M, Pedersen C, Okulicz JF, McClure M, Babiker A, Weber J, Fidler S; INSIGHT SMART and SPARTAC Investigators. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One 2012;7:e43754.
  10. Mugisha JO, Donegan K, Fidler S, Ramjee G, Hodson A, Dunn DT, Porter K, Kaleebu P. Mean Corpuscular Volume as a Marker for Adherence to Zidovudine-Containing Therapy in HIV-Infected Adults. Open AIDS J 2012;6:45-52.

2015

  1. Hamlyn E, Stöhr W, Cooper DA, Fisher M, Tambussi G, Schechter M, Miro JM, Vanobberghen F, Babiker A, Weber J, McClure M, Porter K and Fidler S On Behalf Of The SPARTAC Investigators. The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on Interleukin-6 and D-dimer levels. AIDS 2015 (In Press).

2014

  1. Frater J, Ewings F, Hurst J, Brown H, Robinson N, Fidler S, Babiker A, Weber J, Porter K, Phillips RE on behalf of the SPARTAC Trial Investigators. HIV-1 Specific CD4 Responses in Primary HIV-1 Infection predict disease progression: the SPARTAC Trial. AIDS 2014;28:699-708.
  2. May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, Hay P, Johnson M, Palfreeman A, Gilson R, Chadwick D, Martin F, Hill T, Walsh J, Post F, Fisher M, Ainsworth J, Jose S, Leen C, Nelson M, Anderson J, Sabin C; for the UK Collaborative HIV Cohort (UK CHIC) Study. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy: UK cohort study. AIDS 2014;28:1193-202.
  3. van der Helm JJ, Geskus R, Lodi S, Meyer L, Schuitemaker H, Gunsenheimer-Bartmeyer B, d'Arminio Monforte A, Olson A, Touloumi G, Sabin C, Porter K, Prins M on behalf of CASCADE Collaboration in EuroCoord. Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. Lancet HIV 2014;1;e41–e48.
  4. Pantazis N, Porter K, Costagliola D, De Luca A, Ghosn J, Guiguet M, Johnson A, Kelleher AD, Morrison C, Thiebaut R, Wittkop L and Touloumi G on behalf of CASCADE Collaboration in EuroCoord. Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study. Lancet HIV 2014;1:e119–e126.
  5. Case KK, Hallett TB, Gregson S, Porter K, Ghys PD. Development and future directions for the Joint United Nations Programme on HIV/AIDS estimates. AIDS 2014;28 Suppl 4:S411-4.

2013

  1. SPARTAC Trial Investigators, Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, Rees H, Fisher M, Schechter M, Kaleebu P, Tambussi G, Kinloch S, Miro JM, Kelleher A, McClure M, Kaye S, Gabriel M, Phillips R, Weber J, Babiker A. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013;368:207-17.
  2. van der Helm J, Geskus R, Sabin C, Meyer L, Del Amo J, Chêne G, Dorrucci M, Muga R, Porter K, Prins M; CASCADE collaboration in EuroCoord.  Effect Of HCV Infection On Cause-Specific Mortality Following HIV Seroconversion Before And After 1997. .
  3. Touloumi G, Pantazis N, Pillay D, Paraskevis D, Chaix ML, Bucher HC, Kücherer C, Zangerle R, Kran AM, Porter K; on behalf of the CASCADE collaboration in EuroCoord. Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts. Clin Infect Dis 2013 2013;56:888-97.
  4. Lodi S, Del Amo J, d'Arminio Monforte A, Abgrall S, Sabin C, Morrison C, Furrer H, Muga R, Porter K, Girardi E; on behalf of the CASCADE collaboration in EuroCoord. Risk of tuberculosis following HIV seroconversion in high-income countries. Thorax 2013;68:207-13

HIV clinical cohorts

Kholoud has worked in HIV since 1986 and with the MRC Clinical Trials Unit at University College London, where she is based, since 1994 leading an epidemiology programme of work in HIV research in the unit. She gained an MSc in Medical Statistics at the London School of Hygiene and Tropical Medicine and a PhD in AIDS and HIV Infection at University College London.

Her main research interests are in HIV natural history and primary HIV infection. Most of her work has been within industrialised country cohorts although she has also co-ordinated SPARTAC, a randomised controlled trial recruiting in Uganda and South Africa, and within Evidence for Action, an international consortium evaluating antiretroviral therapy roll-out programmes in Africa. She is Project Leader for the UK Register of HIV Seroconverters and CASCADE, an EU-funded collaboration of HIV seroconverter cohorts. CASCADE became part of a large Network of Excellence, EuroCoord, which she also leads.

Kholoud has collaborated widely within the UK and internationally with colleagues in European, Australian and north American research institutions. Aside from editorial work for AIDS, BMC Public Health, the Open AIDS Journal and Osong Public Health and Research Perspectives, she is a regular reviewer for several medical journals and conference abstracts. She also organises an annual HIV cohorts workshop, the International Workshop for HIV Observational Databases (IWHOD).